Catherine Coste Net Worth

The estimated Net Worth of Catherine Coste is at least 13.6 千$ dollars as of 26 January 2023. Ms. Coste owns over 2,190 units of Biomerica stock worth over 13,619$ and over the last 4 years she sold BMRA stock worth over 0$. In addition, she makes 0$ as Independent Director at Biomerica.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Coste BMRA stock SEC Form 4 insiders trading

Catherine has made over 2 trades of the Biomerica stock since 2020, according to the Form 4 filled with the SEC. Most recently she bought 2,190 units of BMRA stock worth 6,482$ on 26 January 2023.

The largest trade she's ever made was buying 9,100 units of Biomerica stock on 26 October 2020 worth over 49,595$. On average, Catherine trades about 2,258 units every 164 days since 2020. As of 26 January 2023 she still owns at least 43,790 units of Biomerica stock.

You can see the complete history of Ms. Coste stock trades at the bottom of the page.

Catherine Coste biography

Catherine Coste CPA serves as Independent Director of the Company. Ms. Coste recently retired from Deloitte and Touche, where she was a senior partner and served as Deloitte’s Life Sciences Industry Executive Leader. She spent 32 years in both corporate and professional services positions leading global finance, internal audit and operations teams. During her career at Deloitte, Ms. Coste was directly involved with over 30 life science corporations, the majority of which were large-cap and medium-cap public corporations. Ms. Coste also has extensive public company Board experience, often attending multiple Board Committee meetings per month. Ms. Coste also has extensive experience in Sarbanes-Oxley compliance, corporate risk analysis and management, cyber risk assessment, fraud prevention, IT systems analysis and upgrades, internal controls and corporate governance. Ms. Coste is a Certified Public Accountant.

How old is Catherine Coste?

Catherine Coste is 54, she's been the Independent Director of Biomerica since 2020. There are 7 older and 2 younger executives at Biomerica. The oldest executive at Biomerica Inc. is Francis Cano, 76, who is the Independent Director.

Insiders trading at Biomerica

Over the last 12 years, insiders at Biomerica have traded over 80,900$ worth of Biomerica stock and bought 151,277 units worth 334,788$ . The most active insiders traders include Mark A Sirgo、David Moatazedi、John P. Kenny. On average, Biomerica executives and independent directors trade stock every 61 days with the average trade being worth of 3,349$. The most recent stock trade was executed by Zackary S. Irani on 25 May 2023, trading 700 units of BMRA stock currently worth 1,113$.

What does Biomerica do?

biomerica, inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. the company’s products are designed to enhance health and well-being, while reducing total healthcare costs. biomerica primarily focuses on products for gastrointestinal disease, diabetes and esoteric testing. the biomerica infoods® ibs product identifies patient specific foods that when removed may alleviate an individual's ibs symptoms. this patent pending diagnostic guided therapy is designed to allow for a patient specific guided dietary regimen to improve irritable bowel syndrome (ibs) outcomes. the point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for wh

Complete history of Ms. Coste stock trades at Biomerica

Biomerica executives and stock owners

Biomerica executives and other stock owners filed with the SEC include:

• Zackary Irani,
  Chairman of the Board, Chief Executive Officer
• Steven Sloan,
  CFO & Treasurer
• Janet Moore,
  Treasurer, Secretary, Director
• Zackary S. Irani,
  Chairman & CEO
• Allen C. Barbieri,
  Exec. Vice-Chairman & Corp. Sec.
• Mark Sirgo,
  Independent Director
• Jane Emerson,
  Independent Director
• Catherine Coste,
  Independent Director
• Francis Cano,
  Independent Director
• Allen Barbieri,
  Lead Independent Executive Vice Chairman of the Board
• Steven Sloan,
  Chief Financial Officer
• Robert W. Carlson,
  Chief Commercial Officer
• Hans Boehringer,
  Sr. VP of POC R&D
• Lucy Liu Ph.D.,
  Director of Manufacturing & Technical Operations
• David Moatazedi,
  Director
• Francis E Capitanio,
  President
• Janet Trust Dtd 8/21/98 Moore,
  
• John P. Kenny,
  Director
• Gary Lu,
  Chief Financial Officer